Despite the uncertainty of how the Food and Drug Administration will regulate the use of CBD in food and other products, lawyers familiar with the industry say regulators will be interested in learning about labeling, concentration levels and the supply chain of CBD during the agency's first public hearing on CBD in April.

Jennifer Fisher, a partner and team leader of the cannabis practice at Duane Morris in San Francisco, said regulators will likely want to know about things such as product testing and how the concentration of CBD will be controlled.

“There is less of a concern with the low dose of CBD, but the high doses cause concern,” Fisher said.

Kathleen Sanzo, a partner at Morgan, Lewis & Bockius in Washington, D.C., said there will be concerns surrounding the CBD supply chain.

“There are manufacturing issues,” Sanzo said. “How do you follow that product through the supply chain?”

Fisher agreed. “They're going to want to know how consumers or retailers are going to verify that it is derived from hemp,” she explained.

CBD is illegal to use in food on the federal level.

Seth Goldberg, a partner and team leader at Duane Morris in Philadelphia, said with any federal rules or law that could govern CBD distribution, there will likely be some kind of pre-emption over existing state laws. Some states do allow the sale of certain CBD products.

“I think the FDA is going to be particularly focused on whether or not these products are going to be marketed as health products,” Goldberg said.

Besides ingredients for food, CBD has been marketed in products related to skin care and stress relief.

Goldberg said stakeholders believe there is a real need for uniformity among the state laws and federal law.

Outgoing FDA commissioner Dr. Scott Gottlieb has said that unless Congress steps in and passes legislation on the sale of CBD products, it could take the FDA years to come up with a rule for it.

“Any kind of rule-making will take years,” Sanzo said.

She explained the FDA is going to want to see all of the data the industry has available on the topic.

“FDA has other demands that the industry is not going to be in a position to offer,” Sanzo said.

Sanzo said two of the people who are on the committee, Amy Abernathy, the FDA's principal deputy commissioner, and Lowell Schiller, the FDA's acting associate commissioner for policy, have a wide range of experience in government. She said whatever the rules come to be, they will be thought out.

“They are going to have a lot of interesting ideas on how to make the product available in the U.S.,” she said.